Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar Subcutaneous Injection in Advanced NSCLC
NCT02652234Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Aug 2015
- Primary completion
- Jun 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of endostar in non-small cell lung cancer (NSCLC), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Incidence of Adverse Events. Status: unknown.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02652234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652234.